Illumine Investment Management Files 13F for May 4

Illumine Investment Management submitted a Form 13F disclosure on May 4, 2026, reporting its U.S. long equity holdings for the quarter ended March 31, 2026. The filing, summarized by Investing.com on May 4, 2026 and available through the SEC EDGAR system, lists 48 distinct positions with a reported aggregate market value of $412.3 million. Top exposures highlighted in the filing include Nvidia (NVDA), Apple (AAPL), Microsoft (MSFT), Amazon (AMZN) and Tesla (TSLA), which together comprised a concentrated portion of the reported portfolio. This filing provides a window into Illumine's positioning entering the second quarter of 2026 and offers granular signals about sector tilts, concentration risk and potential trading flow. Institutional investors should treat the 13F as a lagged disclosure tool; while informative for positioning trends, it does not capture intramonth trading or derivative exposure.

Context

Illumine's May 4, 2026 Form 13F covers the quarter ended March 31, 2026, consistent with the SEC's calendar for institutional investment manager reporting (SEC EDGAR, Form 13F, filed May 4, 2026). The fund disclosed 48 reporting line items and an aggregate disclosed market value of $412.3 million, making it a mid-sized U.S. equity long-only portfolio in the context of publicly reported managers. The filing date and period are notable because they capture portfolio adjustments made during the market environment of early 2026, which included a 7.4% rebound in the S&P 500 through March 31, 2026 compared with year-end 2025 performance metrics.

Illumine's concentration in mega-cap technology and consumer names aligns with broader industry trends where the largest five positions constituted roughly 60-70% of many managers' disclosed portfolios in early 2026. For comparative context, the median active large-cap manager in the SPIVA universe held roughly 28 positions at quarter-end 2025; Illumine's 48 positions imply a more diversified approach versus the median concentrated manager but still shows clear top-weight biases. The Form 13F does not include cash, short positions, or most derivatives, therefore the disclosed $412.3 million should be interpreted as a floor for net exposure rather than a complete balance-sheet view.

Regulatory and timing context matters for interpretation. The 13F is filed within 45 days of quarter-end and reflects holdings as of the last day of the quarter, not subsequent allocation moves. This lag can distort short-term inferences: for instance, if Illumine materially rebalanced in April or early May 2026, those moves will not be visible in this filing. Readers should cross-reference subsequent 13F amendments, press releases, or direct manager disclosures when inferring forward-looking positioning.

Data Deep Dive

The filing lists NVDA as Illumine's largest disclosed position, representing 18.2% of the reported U.S. long equity market value, according to the Investing.com summary published May 4, 2026 and the SEC filing. Apple and Microsoft rank second and third, at 15.4% and 12.6% respectively, with Amazon at 8.1% and Tesla at 6.2%. Those five names together accounted for an estimated 60.5% of the disclosed portfolio, a concentration level that materially exceeds the equal-weight benchmark and implies significant active bets in large-cap growth names.

Quarter-on-quarter behavior in the filing shows a 22% increase in the NVDA position versus the prior quarter and a 4% reduction in AAPL exposure, signaling a tactical overweight into semiconductor-led AI adoption narratives while trimming defensive mega-cap consumer hardware exposure. These percentage moves are derived from line-item market values reported in the two sequential 13F filings (SEC EDGAR filings dated Feb 4, 2026 and May 4, 2026) and suggest Illumine repositioned toward accelerating earnings expectations for semiconductor and AI infrastructure names in Q1 2026.

Holdings outside the top five include mid-cap industrials and select healthcare names that together constitute the remaining ~39.5% of disclosed value. Geography is notable: the 13F is U.S.-only by design, but Illumine's public commentary on its website indicates contemporaneous non-U.S. equity exposure through separate accounts, which are not reflected in the 13F. For investors comparing Illumine with peers, the allocation profile is statistically closer to growth-focused multi-cap managers than to balanced or value-oriented shops; relative to the Russell 1000 Growth index, Illumine's top-five overweight is approximately 1,400 basis points higher as of March 31, 2026.

Sector Implications

Illumine's heavy weighting in semiconductors and software suggests conviction in the AI-capex cycle and cloud compute demand that dominated Q1 2026 market narratives. NVDA's 18.2% share of Illumine's disclosed portfolio materially exceeds NVDA's weighting in the S&P 500 (which was approximately 6.8% as of March 31, 2026), indicating a concentrated idiosyncratic bet rather than a market-cap weighted index replication. This degree of active risk can amplify performance both on upside reratings and downside shocks; should semiconductor capital expenditure slow, funds with similar tilts would exhibit correlated drawdowns.

In consumer tech, the reduced exposure to Apple (down 4% QoQ in disclosed market value) may reflect profit-taking after the stock's 19% return year-to-date through March 31, 2026, or a reallocation to higher growth cyclicals. For peers in large-cap growth universes, Illumine's mix is notable because it integrates both structural AI winners and cyclically exposed consumer/transportation names like Tesla, which the filing shows as a 6.2% position.

From a market microstructure viewpoint, the 13F signals potential flow: if Illumine were to rebalance toward or away from NVDA at scale, that could generate execution pressure in the shares given NVDA's liquidity profile. However, the public filing does not disclose trade intent or horizon, and execution could be achieved via options and other instruments outside the 13F scope. Institutional counterparties should therefore treat the 13F as a directional signal rather than a precise trading blueprint.

Risk Assessment

The concentration risk in Illumine's disclosed portfolio is the primary near-term risk. With the top five names making up c.60.5% of reported market value, an idiosyncratic shock to any one of those companies could meaningfully impact reported performance. For example, a 15% drop in NVDA, given its 18.2% weight, would mechanically reduce the reported portfolio value by roughly 2.7 percentage points before accounting for correlation with other holdings.

Market-cap bias risk is also present. Illumine's tilt toward mega-cap growth leaves it exposed to de-rating cycles that typically affect high-valuation cohorts first when discount rates rise or earnings revisions disappoint. Conversely, the filing shows defensive sectors underrepresented relative to broader benchmarks, potentially increasing portfolio beta to cyclical slowdowns. Liquidity risk applies unevenly: while NVDA and AAPL are highly liquid, smaller positions in mid-cap healthcare have thinner daily volumes and could incur larger transaction costs if scaled up or down rapidly.

Operationally, the 13F's lack of derivative transparency introduces model risk for counterparties and allocators attempting to reconstruct true net exposure. Shorts, swaps, and non-U.S. holdings will not appear; therefore, the disclosed long positions are only one axis of exposure. Allocators should augment 13F analysis with trade confirmations, separate-account reporting, and conversations with the manager to form a complete risk picture.

Fazen Markets Perspective

Fazen Markets' view is that Illumine's pattern of adding to NVDA and reducing Apple is a rational but higher-conviction posture that reflects asymmetric payoff expectations in AI infrastructure versus consumer hardware. The contrarian insight is that such concentrated bets, while headline-grabbing, may indicate manager preference for event-driven alpha over broad macro hedging. This can be advantageous if the AI investment cycle continues to surprise to the upside, but it creates path-dependent returns that will look very different in stress periods than in bull markets.

We further note that many mid-sized managers use options and structured overlays that escape 13F detection; therefore, the presence of long-dated call writing or collar strategies could materially alter the risk/return profile implied by the disclosed long positions. Our proprietary transaction-cost model suggests that if Illumine were to increase NVDA exposure from 18.2% to 25% of the disclosed portfolio within a 30-day window, market impact costs would likely erode a non-trivial portion of the expected alpha unless execution is staggered or synthetic instruments are used.

Given these dynamics, allocators should balance headline concentration with execution and liquidity considerations, and where possible, verify via direct dialogue. For more on manager disclosure analysis and portfolio reconstruction, see our institutional resources on topic and detailed methodology pages at topic.

Outlook

Looking ahead to the next set of disclosures, the market will watch Illumine's potential reweighting in response to Q2 2026 macro headlines, including any changes in Fed guidance and earnings surprises from the top-weighted names. If NVDA and peers report stronger-than-expected earnings and guidance in late July and August 2026, Illumine's Q3 positioning as revealed in the next 13F could tighten further around semiconductors, compounding sector concentration.

Conversely, macro uncertainty or negative earnings momentum in large-cap growth stocks would likely prompt a de-risking that should be visible as smaller NVDA and MSFT lines in the subsequent filing. Institutional investors should therefore track intra-quarter disclosures, such as 8-Ks or 13D/G filings if activist activity occurs, to capture changes that fall outside the 13F cadence.

Practically, allocators using 13F data for signals should apply a multi-quarter smoothing approach and combine filings with execution cost simulations. A quarterly snapshot provides directional value but must be integrated with other data for portfolio construction decisions; our white papers on 13F reconstruction outline a repeatable three-layer methodology for that purpose available at topic.

FAQ

Q: Does the 13F show Illumine's total assets under management?

A: No. A Form 13F reports only long U.S.-listed equity positions above reporting thresholds as of quarter-end. It does not show total assets under management, cash, short positions, derivatives, or non-U.S. holdings. For a fuller AUM picture, investors should request primary disclosures from the manager or consult regulatory filings where applicable.

Q: How should allocators interpret changes between sequential 13F filings?

A: Sequential 13F comparisons are useful to identify directionality—whether positions were accumulated or trimmed between quarter-ends—but they do not reveal intramonth trades or exposure via derivatives. A quarter-on-quarter increase in disclosed market value for a given stock could reflect price appreciation rather than net buys; therefore, cross-referencing share counts and reported market values is critical to distinguish trading from mark-to-market effects.

Bottom Line

Illumine's May 4, 2026 Form 13F reveals concentrated conviction in AI-related mega-cap names, notably NVDA, and a portfolio structure that favors growth exposure over defensive diversification. Institutional readers should treat the filing as a directional, lagged input and combine it with execution, liquidity and derivative analysis before drawing conclusions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.